SPY305.55+1.23 0.40%
DIA255.27+0.98 0.39%
IXIC9,552.05+62.18 0.66%

Genmab Highlights Data To Be Presented At European Hematology Association Congress Jun. 11-14

Genmab A/S (NASDAQ:GMAB) announced today that eight industry sponsored abstracts regarding Genmab and partner programs were accepted for presentation at the 25th European Hematology Association (EHA) EHA25 Virtual

Benzinga · 05/14/2020 13:42

Genmab A/S (NASDAQ:GMAB) announced today that eight industry sponsored abstracts regarding Genmab and partner programs were accepted for presentation at the 25th European Hematology Association (EHA) EHA25 Virtual Congress 2020, taking place virtually on June 11-14, 2020. A list of accepted Industry-sponsored abstracts featured at the congress includes two abstracts on epcoritamab (DuoBody®-CD3xCD20), one on HexaBody®-CD38, one on DuoHexaBody®-CD37 and four daratumumab abstracts. The abstracts have been published on the EHA website and may be accessed via www.ehaweb.org. All e-Poster presentations will be made available on the on-demand Virtual Congress platform Friday, June 12 at 08:30 CEST.

“We are very pleased to see that once again a broad spectrum of data from Genmab’s innovative clinical and pre-clinical proprietary pipeline has been accepted for presentation at the prestigious EHA Congress,” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

Industry-Sponsored Abstracts are as follows:

Epcoritamab (DuoBody-CD3xCD20):
Subcutaneous epcoritamab (DuoBody-CD3×CD20) induces complete response in heavily pre-treated patients with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma: Phase 1/2 dose escalation

Evaluation of pharmacodynamic biomarkers of epcoritamab (GEN3013; CD3CD20): Results from a Phase 1/2 dose-escalation study in relapsed/refractory B-cell Non-Hodgkin Lymphoma

HexaBody-CD38:
Superior anti-tumor activity of HexaBody-CD38 in preclinical models of Multiple Myeloma, B Cell Lymphoma and AML

DuoHexaBody-CD37:
DuoHexaBody-CD37 shows potent anti-tumor activity in pre-clinical B-cell lymphoma models in vitro and in vivo

Daratumumab (Submitted by Janssen Biotech, Inc.):
Phase 3 Study of Daratumumab/Bortezomib/Dexamethasone Versus Bortezomib/Dexamethasone in Chinese Patients with Relapsed/Refractory Multiple Myeloma: MMY3009 (LEPUS)

Corticosteriod Tapering in Patients with Relapsed or Refractory Multiple Myeloma Receiving Subcutaneous Daratumumab: Part 3 of the Open-label, Multicenter, Phase 1b PAVO Study

Impact of Depth of Response and Minimal Residual Disease on Health-Related Quality of Life of Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma

Daratumumab + Bortezomib, Thalidomide, and Dexamethasone in Transplant-eligible Newly Diagnosed Multiple Myeloma: Baseline slimCRAB-based Subgroup Analysis of CASSIOPEIA